Mr. Malley has served as a member of our Board of Directors since October 2015. Mr. Malley has served as President of Mossrock Capital, LLC, or Mossrock, a private investment firm, since May 2007. He worked for Janus Mutual Funds in positions of increasing responsibility from April 1991 to May 2007. From January 1999 to May 2007, Mr. Malley served as the portfolio manager of the Janus Global Life Sciences Fund and also led the Janus Healthcare team of analysts. From 1991 to 1998 Mr. Malley served as an equity analyst for Janus covering, among others, healthcare and biotechnology stocks. Mr. Malley has been a director of OvaScience, Inc., a public life sciences company, since October 2012, and BeiGene, Ltd., a public biotechnology company, since January 2016. Previously, he served as a director of Synageva BioPharma Corp., a public biopharmaceutical company, from 2006 to 2015, until its acquisition by Alexion Pharmaceuticals, Inc., Puma Biotechnology, Inc., a public biopharmaceutical company, from 2011 to 2015, and Cougar Biotechnology, Inc., a public biopharmaceutical company, from 2007 to 2009, until its acquisition by Johnson and Johnson. Mr. Malley holds a B.S. in Biology from Stanford University.
What is Thomas Malley's net worth?
The estimated net worth of Thomas Malley is at least $150.30 thousand as of August 14th, 2025. Mr. Malley owns 12,546 shares of Kura Oncology stock worth more than $150,301 as of December 4th. This net worth approximation does not reflect any other assets that Mr. Malley may own. Learn More about Thomas Malley's net worth.
How do I contact Thomas Malley?
Has Thomas Malley been buying or selling shares of Kura Oncology?
Thomas Malley has not been actively trading shares of Kura Oncology during the past quarter. Most recently, on Friday, June 16th, Thomas Malley bought 50,000 shares of Kura Oncology stock. The stock was acquired at an average cost of $11.50 per share, with a total value of $575,000.00. Following the completion of the transaction, the director now directly owns 139,557 shares of the company's stock, valued at $1,604,905.50. Learn More on Thomas Malley's trading history.
Who are Kura Oncology's active insiders?
Are insiders buying or selling shares of Kura Oncology?
In the last twelve months, Kura Oncology insiders bought shares 1 times. They purchased a total of 50,000 shares worth more than $410,000.00. In the last twelve months, insiders at the sold shares 16 times. They sold a total of 137,521 shares worth more than $1,308,039.69. The most recent insider tranaction occured on November, 14th when insider Teresa Brophy Bair sold 8,804 shares worth more than $98,428.72. Insiders at Kura Oncology own 6.4% of the company.
Learn More about insider trades at Kura Oncology. Information on this page was last updated on 11/14/2025.
